Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meso-tetra-4-pyridyl porphine (MTP) is a synthetic porphyrin derivative that serves as a photosensitizer in photodynamic therapy (PDT). It is characterized by its ability to non-covalently assemble with single-stranded DNA (ssDNA) to form stable, nano-sized complexes (PDN) under physiological conditions. These complexes are designed for pH-dependent release, dissociating in acidic environments such as the endosomal compartments of cancer cells (pH ~5.1) where the pyridyl nitrogens of MTP become protonated. Upon exposure to light, MTP generates reactive oxygen species (ROS), which induce localized membrane damage and lipid peroxidation, leading to cell death. Research conducted at Wake Forest University has demonstrated that MTP-DNA complexes exhibit significant anti-tumor activity in bladder cancer xenograft models, suggesting potential applications in targeted cancer treatment and drug delivery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meso-tetra-4-pyridyl porphine.